Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Mar 27, 2021 5:31pm
92 Views
Post# 32893617

RE:RE:RE:RE:RE:RE:RE:NASH and fructose

RE:RE:RE:RE:RE:RE:RE:NASH and fructoseOne thing is sure, the cure to NASH would be an enzyme taken before a meal that would be able to convert fructose to glucose in the small intestine before absorbtion. Robert Lustig wrote a scientific paper in 2013 with the title: "Fructose it's alcohol without the buzz". All the fructose that we eat end up in the liver, and the metabolism byproduct it generates is very similar to alcohol (ethanol). So NASH (non alcoholic steatohepatitis) could also be called, fructose steatohepatitis. Add to that that many patients are ingesting some alcohol and too much fructose. Then it is easy to understand the prevalence of this condition.

https://academic.oup.com/advances/article/4/2/226/4591631?login=true
<< Previous
Bullboard Posts
Next >>